Vyome Biosciences Raises $8M in Series B Funding

Vyome Biosciences, a Delhi, India-based dermatology company, raised $8m in Series B funding.

The round was led by Sabre Partners with participation from existing investors Kalaari Capital and Aarin Capital.

The company intends to use the funds to complete critical milestones of USFDA filings and Phase 1 & Phase 2 clinical research for some of its lead compounds and other development and commercialization efforts of its Rx and OTC pipeline.

Co-founded by Dr. Shiladitya Sengupta, co-chair at the Center for Regenerative Therapeutics at Brigham & Women’s Hospital in Boston and assistant professor of Medicine at Harvard Medical School, Dr. Rajesh Gokhale, director of the Institute of Genomics & Integrative Biology in Delhi, CEO N. Venkat, who earlier worked as CEO of Emami and President of Shantha Biotechnics and Rajiv Mantri, Executive Director, Navam Capital, Vyome focuses on developing novel treatments for hard to treat and refractory skin conditions such as persistent dandruff and skin fungal infections, resistant acne and other skin bacterial infections.



Join the discussion